Philip Armstrong

June 11, 2012Toronto-based 1DegreeBio closes Series B funding round with Macmillan Digital Science

1DegreeBio Inc., the largest independent review website for research-grade antibodies and related life science products has closed a Series B round of funding, led by Macmillan Digital Science Limited. Philip Armstrong, CEO of Jovian Capital Corporation, and 1DegreeBio senior management also participated in the round.

More Blogs